← Back to Search

Cytokine

Interleukin-2 for Kidney Cancer

Phase 2
Waitlist Available
Research Sponsored by Cancer Biotherapy Research Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cardiovascular: No prior myocardial infarction within 6 months, No LVEF less than 35%, No primary cardiac arrhythmias beyond occasional PVCs, No angina, No uncontrolled congestive heart failure, No cerebrovascular accident
Pulmonary: No dyspnea at rest or requirement for supplemental oxygen, Oxygen saturation greater than 90% for patients with symptomatic lung disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying how well interleukin-2 works in treating patients with kidney cancer that has spread to other parts of the body.

Who is the study for?
This trial is for adults who've had surgery to remove stage III or IV kidney cancer and are at high risk of the cancer coming back. They should not have brain metastases, recent heart attacks, certain heart/lung conditions, psychiatric disorders, or be pregnant/nursing. Participants must meet specific health criteria and agree to avoid pregnancy.Check my eligibility
What is being tested?
The study is testing Interleukin-2's effectiveness in preventing the return of kidney cancer after surgical removal. It's a Phase II trial focusing on how well this treatment stimulates white blood cells to destroy any remaining cancer cells.See study design
What are the potential side effects?
Interleukin-2 can cause flu-like symptoms such as fever and chills, fatigue, nausea, vomiting, diarrhea, skin rash and itching. It may also affect normal blood counts and organ function which will be closely monitored during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My heart is healthy with no recent major issues.
Select...
I don't need extra oxygen and can breathe normally.
Select...
My kidney cancer was removed surgically and is at high risk of coming back.
Select...
My cancer has spread beyond a specific area in my kidney.
Select...
My liver function tests are within normal limits.
Select...
My cancer has spread to the renal vein or vena cava.
Select...
All my cancerous lymph nodes have been surgically removed.
Select...
My cancer has not spread to my brain.
Select...
My creatinine level is 1.9 mg/dL or lower.
Select...
My cancer has spread to my adrenal gland or nearby tissues but not beyond a specific boundary.
Select...
My cancer has spread to the large vein above my stomach.
Select...
All of my cancer that spread has been surgically removed.
Select...
I am able to get out of my bed or chair and move around.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Cancer Biotherapy Research GroupLead Sponsor
12 Previous Clinical Trials
100 Total Patients Enrolled
Datchen F. Tai, MDStudy ChairCancer Biotherapy Research Group
1 Previous Clinical Trials
30 Total Patients Enrolled

Media Library

Interleukin-2 (Cytokine) Clinical Trial Eligibility Overview. Trial Name: NCT00003604 — Phase 2
Kidney Cancer Clinical Trial 2023: Interleukin-2 Highlights & Side Effects. Trial Name: NCT00003604 — Phase 2
Interleukin-2 (Cytokine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00003604 — Phase 2
Kidney Cancer Research Study Groups:

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How have patient safety measures been implemented for this procedure?

"Due to the Phase 2 status of this treatment, which suggests some evidence of safety but a lack thereof regarding efficacy, our team at Power has rated its safety as a 2."

Answered by AI

Is this research project currently accepting participants?

"At present, this research study is not actively enrolling patients. It was initially posted on October 1st 1997 and last modified November 5th 2013. However, there are 423 other clinical trials that are presently seeking participants."

Answered by AI
~1 spots leftby Mar 2025